Dr. Finn on PD 0332991 Plus Letrozole in Breast Cancer

Richard S. Finn, MD
Published: Wednesday, Dec 05, 2012

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, describes results from a phase II study that examined PD 0332991, an oral selective inhibitor of cyclin-dependent kinase 4/6, in combination with letrozole as a treatment for postmenopausal women with metastatic ER-positive breast cancer.

In the trial, 165 patients were randomized 1:1 to receive letrozole alone or in combination with PD 0332991. Patients were further stratified into two parts based on molecular characteristics. Part 2 of the study contained patients with CCND1 amplification and/or a loss of p16 expression.

Finn explains that the addition of PD 0332991 to letrozole resulted in a dramatic improvement between all subgroups of the trial. The median progression-free survival (PFS) benefit for the combination was 26.1 months compared to 7.5 months for letrozole alone (HR = 0.37; P < .001).

A phase III trial is planned to begin in 2013 to further examine the efficacy of PD 0332991 in breast cancer.

<<< View coverage from the 2012 SABCS

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, describes results from a phase II study that examined PD 0332991, an oral selective inhibitor of cyclin-dependent kinase 4/6, in combination with letrozole as a treatment for postmenopausal women with metastatic ER-positive breast cancer.

In the trial, 165 patients were randomized 1:1 to receive letrozole alone or in combination with PD 0332991. Patients were further stratified into two parts based on molecular characteristics. Part 2 of the study contained patients with CCND1 amplification and/or a loss of p16 expression.

Finn explains that the addition of PD 0332991 to letrozole resulted in a dramatic improvement between all subgroups of the trial. The median progression-free survival (PFS) benefit for the combination was 26.1 months compared to 7.5 months for letrozole alone (HR = 0.37; P < .001).

A phase III trial is planned to begin in 2013 to further examine the efficacy of PD 0332991 in breast cancer.

<<< View coverage from the 2012 SABCS




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x